title: Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.
abstract: OBJECTIVE
  To identify factors associated with the decisions of the Federal Department of Home Affairs concerning coverage with evidence development (CED) for contested novel medical technologies in Switzerland.
  
  
  METHODS
  Quantitative, retrospective, descriptive analysis of publicly available material and prospective, structured, qualitative interviews with key stakeholders.
  
  
  METHODS
  All 152 controversial medical services decided on by the Federal Commission on Health Insurance Benefits within the framework of the new federal law on health insurance in Switzerland from 1997 to 2013, with focus on 33 technologies assigned initially to CED and 33 to evidence development without coverage.
  
  
  METHODS
  Factors associated with numbers and type of contested services assigned to CED per year, the duration and final outcome of the evaluations and perceptions of key stakeholders.
  
  
  RESULTS
  The rate of CED decisions (82 total; median 1.5/year; range 0-9/year), the time to final decision (4.5 years median; 0.75 to +11 years) and the probability of a final 'yes' varied over time. In logistic regression models, the change of office of the commission provided the best explanation for the observed outcomes. Good intentions but absence of scientific criteria for decisions were reported as major comments by the stakeholders.
  
  
  CONCLUSIONS
  The introduction of CED enabled access to some promising technologies early in their life cycle, and might have triggered establishment of registries and research. Impact on patients' outcome and costs remain unknown. The primary association of institutional changes with measured end points illustrates the need for evaluation of the current health technology assessment (HTA) system.
authors.affiliation: Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
authors.forename: Urs
authors.initials: U
authors.lastname: Brügger
authors.affiliation: Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
authors.forename: Bruno
authors.initials: B
authors.lastname: Horisberger
authors.affiliation: Institute for Data Analysis and Process Design, Zurich University of Applied Sciences, Winterthur, Switzerland.
authors.forename: Alexander
authors.initials: A
authors.lastname: Ruckstuhl
authors.affiliation: Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
authors.forename: Rafael
authors.initials: R
authors.lastname: Plessow
authors.affiliation: Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
authors.forename: Klaus
authors.initials: K
authors.lastname: Eichler
authors.affiliation: Medical Faculty, University of Basle, Basle, Switzerland.
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
mesh_terms: D003659:Decision Making, Organizational; D019317:Evidence-Based Medicine; D035082:Federal Government; D006801:Humans; D019458:Insurance Coverage; D007348:Insurance, Health; D008137:Longitudinal Studies; D008505:Medical Staff, Hospital; D011446:Prospective Studies; D012189:Retrospective Studies; D013557:Switzerland; D013673:Technology Assessment, Biomedical; D013997:Time Factors
references.citation: Int J Technol Assess Health Care. 2002 Spring;18(2):161-5
references.pmid: 12053415
references.citation: Int J Technol Assess Health Care. 2014 Jul;30(3):253-9
references.pmid: 25100035
references.citation: N Engl J Med. 1982 Oct 21;307(17):1095-100
references.pmid: 6750400
references.citation: Health Aff (Millwood). 2006 Sep-Oct;25(5):1218-30
references.pmid: 16966717
references.citation: Int J Technol Assess Health Care. 2007 Fall;23(4):425-32
references.pmid: 17937829
references.citation: J Gen Intern Med. 2008 Jan;23 Suppl 1:50-6
references.pmid: 18095045
references.citation: Int J Technol Assess Health Care. 2009 Jul;25(3):367-73
references.pmid: 19619356
references.citation: Forsch Komplementmed. 2009 Aug;16(4):216
references.pmid: 19729931
references.citation: Int J Technol Assess Health Care. 2009 Dec;25 Suppl 2:56-67
references.pmid: 20030892
references.citation: Pharmacoeconomics. 2010;28(2):109-11
references.pmid: 20085388
references.citation: Pharmacoeconomics. 2010;28(2):113-42
references.pmid: 20085389
references.citation: Bone Marrow Transplant. 2010 Feb;45(2):219-34
references.pmid: 19584824
references.citation: Health Policy. 2010 Aug;96(3):179-90
references.pmid: 20226559
references.citation: Int J Technol Assess Health Care. 2011 Jan;27(1):77-83
references.pmid: 21262072
references.citation: J Clin Oncol. 2011 May 20;29(15):1980-6
references.pmid: 21483006
references.citation: Haematologica. 2012 Jun;97(6):800-4
references.pmid: 22665529
references.citation: Swiss Med Wkly. 2013;143:w13757
references.pmid: 23443995
references.citation: BMC Health Serv Res. 2013;13:88
references.pmid: 23497271
references.citation: JAMA Intern Med. 2013 Jul 22;173(14):1281-2
references.pmid: 23649323
references.citation: Value Health. 2013 Jul-Aug;16(5):703-19
references.pmid: 23947963
references.citation: J Comp Eff Res. 2013 Jul;2(4):383-91
references.pmid: 24236680
references.citation: Orphanet J Rare Dis. 2013;8:198
references.pmid: 24365263
references.citation: Int J Technol Assess Health Care. 2014 Apr;30(2):179-87
references.pmid: 24806420
references.citation: JAMA. 2014 Jun 25;311(24):2490-8
references.pmid: 25058083
references.citation: Cytotherapy. 2003;5(4):306-8
references.pmid: 12944236